Trials preclinical

The preclinical trials are performed in in vitro and animal studies to assess the biological activity of the new compound. In phase 1 of the clinical trials the safety of a new drug is examined and the dosage is determined by administering the compound to about 20 to 100 healthy volunteers. The focus in phase II is directed onto the issues of safety, evaluation of efficacy, and investigation of side effects in 100 to 300 patient volimteers. More than 1000 patient volunteers are treated with the new drug in phase 111 to prove its efficacy and safety over long-term use. 

Numerous neuropeptides are beheved to be involved with the transmission or inhibition of pain, and the hope is to utilize this approach as a strategy to induce analgesia. Substance P is reported to be a transmitter of nociceptive impulses (39), and therefore antagonists should be analgesic. Capsaicin [404-86-4], C2gH2yN02, is known to deplete substance P and cause analgesia (40), but its side effects are intolerable. Antagonists to bradykinin [58-82-2], a substance known to induce pain (41), have shown some success in preclinical trials. 

The reaction of the (necessarily) cis-oxalato complex with HCI in the last example, ensures the c/s-configuration for the chloro complex on recrystallization, the thermodynamically more stable fra s-isomer forms. fra s-Rupy4Cl2 has Ru-N 2.079 A and Ru—Cl 2.405 A. An imidazole complex (imH) tra s-[RuCl4(im)2] shows promise as a tumour inhibitor and is currently undergoing preclinical trials [135]. 

TLR-9 has also been used to target asthma with several compounds in preclinical trials such as second generation CpG-ODNs and HYB2093. 1018 ISS has also been tested in asthma. Defence against infectious disease is also enhanced through TLR-9. CpGIOlOl was in phase II trails as a Hepatitis C target but has been discontinued. 

Table 4.2 The range of major tests undertaken on a potential new drug during preclinical trials.

In addition, tests for mutagenicity and carcinogenicity are not likely required for most biopharma-ceutical substances. The regulatory guidelines and industrial practices relating to biopharmaceuti-cal preclinical trials thus remain in an evolutionary mode, and each product is taken on a case-by-case basis. An overview of the main preclinical tests undertaken for a sample biopharmaceutical... 

The criteria used by the CBER and CDER regulators in assessing product performance during the drug development process are similar, i.e. safety, quality and efficacy. However, the administrative details can vary in both name and content. Upon concluding preclinical trials, all... 

Some cytokines have already gained approval for medical use. Many more are currently undergoing clinical or preclinical trials. Over the next few chapters the biology and potential medical applications of these cytokines will be discussed in detail. The remainder of this chapter concerns itself with the prototypic cytokine family, namely the interferons. 

The annual R D expenditure for biopharmaceuticals is around US 19-20 billion. There are estimated to be 2500 biopharmaceuticals in the discovery phase, 900 in preclinical trials, and 1600 in clinical trials. This represents 44% of all drugs in the development phase and 27% of all drugs in both preclinical and clinical trials. The most common target is cancer and monoclonal antibodies and vaccines have the largest amount of R D activities. 

Pessina, A., Malerba, 1. and Gribaldo, L. (2005) Hematotoxicity testing by cell clonogenic assay in drug development and preclinical trials. Current Pharmaceutical Design, 11, 1055-1065. 

In preclinical trials, efficiency remains low, but expression has been noted to last for several weeks, and there has been no signihcant inflammatory response. 

The first epithilone, a highly potent microtubule stabilizer, in advanced clinical development (Phase II) is ZK-EPO (ZK-219447), while fludelone is still in preclinical trials (cf. Chapter 4). 

The efficacy of human G-CSF was initially evaluated in simian preclinical trials. Monkeys treated with subcutaneous injections of G-CSF showed a dose-related increase in polymorphonuclear neutrophils. These initial studies also evaluated two cyclophosphamide-treated animals. G-CSF... 

Sponges are considered as the chemical factory in marine environment because of its immense production of chemically diverse compounds. Other than the chemical diversity, these compounds possess remarkable bioactivities. This great potential has aroused applications of sponge-derived compounds as therapeutics and at present, a number of promising compounds are in clinical and preclinical trials. Recently, nutraceuticals have received considerable interest among the health conscious community because of its multiple therapeutic effects. Natural health-promoting substances... 

David, J. N. and Gordon, M. C. (2004). Marine natural products and related compounds in clinical and advanced preclinical trials. J. Nat. Prod. 67, 1216-1238. 

---